Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Pain 2Neoplasms 2Weight Loss 1Trigger Finger Disorder 1Prostatic Neoplasms 1Pituitary Neoplasms 1Patient Satisfaction 1Nose Neoplasms 1Mucositis 1Menorrhagia 1Median Neuropathy 1Lymphoma, Follicular 1Leiomyoma 1Hemorrhage 1Head and Neck Neoplasms 1Ganglion Cysts 1Esthesioneuroblastoma, Olfactory 1De Quervain Disease 1Cognitive Dysfunction 1Cachexia 1Adenomyosis 1Abnormalities, Radiation-Induced 1

Interventions

Memantine 2acetaminophen, aspirin, caffeine drug combination 1Transcranial Direct Current Stimulation 1Time 1Sugars 1Sirolimus 1Riluzole 1Referral and Consultation 1Ramipril 1Radiotherapy, Intensity-Modulated 1Palliative Care 1Ibuprofen 1Exercise 1Donepezil 1Cognitive Behavioral Therapy 1Cannabidiol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Cognitive Dysfunction × Ibuprofen × Clear all
NCT03186638 2023-09-25

Low-Dose Ibuprofen in Improving Cognitive Impairment in Patients With Cancer

University of Rochester

Phase 2 Completed
87 enrolled 13 charts

Neoplasms, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡